Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Evotec SENASDAQ: EVO

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of €54.75M rose 15.9% year over year, ahead of the -24.8% change in trailing-twelve-month operating expenses. Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +8.9% a year.

Context

  • Operating expenses amounted to 26.1% of revenue in FY2025, down 6.2 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +15.9% holds above the trailing-twelve-month pace of -24.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€54.75M+2.0% QoQ
Last fiscal yearDec 2025
€197.97M-23.1% YoY
LTMMar 2026
€189.23M-24.8% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.9%——
1 year-23.1%——
3-year CAGR+8.9%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

EUR · from the income statement

Latest · FY2025
197.97M EUR
Year-over-year change
-23.1%
4-year CAGR
+15.7%

Operating Expenses vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -24.8% is the 10th highest of 11, against a peer median of +14.3%.
  • Operating expenses amounts to 25.4% of revenue for EVO, versus a peer median of 76.2%.
EVO Competitors
Operating Expenses for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TLRYTilray Brands, Inc.LTM Feb 2026$2.36B USD+49.4%+55.7%200.0%
TDOCTeladoc Health, Inc.LTM Mar 2026$1.84B USD-35.5%-49.1%73.2%
NVCRNovoCure LimitedLTM Mar 2026$690.48M USD+6.8%+7.8%102.4%
PCRXPacira BioSciences, Inc.LTM Mar 2026$560.33M USD-11.1%+10.1%76.2%
AZTAAzenta, Inc.LTM Sep 2026$447.31M USD+59.0%+12.5%71.9%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$295.42M USD+75.4%-24.2%326.5%
SDGRSchrödinger, Inc.LTM Sep 2026$291.15M USD-9.0%+7.7%108.2%
ALVOAlvotechLTM Mar 2026$266M USD+17.6%-9.3%47.5%
PHVSPharvaris N.V.LTM Sep 2026€193.36M EUR+125.2%+25.1%—
EVOEvotec SELTM Mar 2026€189.23M EUR-24.8%+8.9%25.4%
HROWHarrow Health, Inc.LTM Mar 2026$170.99M USD+10.9%+39.3%63.6%
Peer median (excluding EVO) —+14.3%+8.9%76.2%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue618.03M751.45M781.43M796.97M757.26M
Cost of Revenue466.49M577.38M606.38M682.09M694.6M
Gross Profit151.54M174.07M175.05M114.88M62.66M
Gross Margin24.5%23.2%22.4%14.4%8.3%
Research & Development65.7M76.64M68.53M50.86M74.33M
Selling, General & Admin105.45M156.19M169.61M188.2M123.65M
Operating Expenses110.55M153.22M222.56M257.4M197.97M
Depreciation & Amortization70.4M83.2M92.98M101.62M95.55M
EBITDA316.63M(57.61M)24.13M(80.66M)(13.89M)
EBITDA Margin51.2%-7.7%3.1%-10.1%-1.8%
Operating Income41M20.85M(47.51M)(142.52M)(135.31M)
Operating Margin6.6%2.8%-6.1%-17.9%-17.9%
Interest Income2.27M8.34M9.26M2.44M4.25M
Interest Expense9.25M13.15M11.74M11.7M13.87M
Other Income / Expenses195.98M(174.81M)(33.09M)(51.46M)12M
Income Before Tax236.98M(153.96M)(80.59M)(193.98M)(123.31M)
Pre-Tax Margin38.3%-20.5%-10.3%-24.3%-16.3%
Income Tax Expense21.47M21.7M3.32M2.1M(23.88M)
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Net Margin34.9%-23.4%-10.7%-24.6%-13.1%
EPS (Basic)0.65(0.49)(0.23)(0.56)(0.28)
EPS (Diluted)0.65(0.49)(0.23)(0.56)(0.28)
Weighted Avg Shares332.81M353.35M353.87M353.29M355.16M
Weighted Avg Shares (Diluted)332.81M353.41M353.87M354.59M355.16M

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.